Project Grant R42HL140701

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina to develop peptides derived from collagen XVIII for the treatment of pulmonary fibrosis. The project aims to simultaneously test the identified peptides in preclinical models of fibrosis, identify a lead candidate, characterize its efficacy, conduct dose escalation...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $350,000 to Adiutrix Therapeutics LLC to develop a novel anti-fibrotic compound platform to identify and develop first-in-class therapeutics targeting collagen prolyl-4 hydroxylase (C-P4H) activity. The goal is to treat tissue remodeling and fibrosis in underserved diseases such as idiopathic pulmonary fibrosis (IPF), scleroderma skin fibrosis, kidney fibrosis, and intestinal fibrosis...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $728,577 to investigate the role of purinergic signaling in idiopathic pulmonary fibrosis (IPF), a devastating lung disease. The research aims to elucidate how extracellular ATP and the fibroblast-specific ATP receptor P2RX4 regulate profibrotic pathways in lung fibroblasts, with the goal of validating P2RX4 as a novel therapeutic target for IPF. The 4-year...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel drug candidate to treat idiopathic pulmonary fibrosis (IPF). The award of $356,250 will support a two-phase project by Vasarya Therapeutics, Inc. to perform affinity maturation and liability assessment on a tool compound called VSR-H5, which has demonstrated the ability to selectively target and inhibit...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,193,262 to The Regents of the University of California, San Francisco to develop an adeno-associated virus-mediated SGPL1 gene therapy as a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF). The research aims to confirm the efficacy of this gene therapy in reducing lung fibrosis and downstream profibrotic signaling in mouse models and...

This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $499,585 to The University of Texas Health Science Center at Tyler (UTHSCT) to develop and validate a novel two-target fibrinolytic therapy (T2FT) for the treatment of empyema, a serious complication of pneumonia. The goal is to increase the efficacy of the fibrinolytic drug alteplase (ALT) by simultaneously targeting inflammation through a TREM-1...

This R01 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $596,179 over a 5-year period beginning on January 1, 2025 to conduct research on the role of macropinocytosis, a cellular process, in the development of pulmonary fibrosis. The research aims to determine whether inhibiting macropinocytosis can attenuate fibrosis in animal models and cell culture systems, as well as elucidate the molecular mechanisms by...